The conference call was interesting. Talking about competitors they mentioned that it’s not unusual for Drs to try new releases but they tend to come back so the effect is transitory.
On VIV they expect these for both SAVR and especially TAVR to increase as they head towards 2028. Casually saying that it’s good that now patients can have confidence that if they out live their valve they can have a VIV option. They are so casual about it.
The conference call was interesting. Talking about competitors...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.15 |
Change
0.150(2.50%) |
Mkt cap ! $95.31M | |||
| Open | High | Low | Value | Volume |
| $6.00 | $6.15 | $6.00 | $41.13K | 6.816K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 165 | $6.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.20 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |